UPDATE 1

Yahoo NewsUPDATE 1-AstraZeneca suffers setback as drug fails in eye cancer | ReutersReutersUPDATE 1-AstraZeneca suffers setback as drug fails in eye cancer. * Selumetinib fails in Phase III trial for uveal melanoma. * Drug continues to be tested in lung, other cancers. * 2020 consensus sales forecast for selumetinib $305 mln (Adds sales ...AstraZeneca suffers setback as drug fails in eye cancer - Yahoo NewsYahoo Newsall 19 news articles »

Share this post